Cannon, T. L., Rothe, M., Garrett-Mayer, E., Gregory, A., McKean, M., Kadakia, K. C., Pisick, E. P., Adesunloye, B., Nagi, J., Grussie, E., Calfa, C. J., Chahin, M., Thumar, J. R., Nwabudike, S. M., Gim, G., Gregory, A., Hinshaw, D. C., Grantham, G. N., Halabi, S., Schilsky, R. L. (2026). Atezolizumab (A) plus pertuzumab/trastuzumab/hyaluronidase (PHESGO) in patients (pts) with solid tumors with ERBB2 alterations (alt): Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.2644